# ImevaX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/imevax

- Industry: Pharmaceuticals
- Headquarters: Munich, Germany
- Website: www.imevax.com
- Total disclosed funding: $8.5M
- Latest round: Series A (Feb 27, 2015)
- Investors on record: 5

## About

ImevaX is a biotechnology company focused on developing innovative therapies for autoimmune diseases, leveraging advanced genetic and immunological research to create effective, targeted treatment solutions.Founded in 2014 and headquartered in Munich, Germany, ImevaX specializes in the development of therapies for autoimmune diseases. The company raised EUR 7.5 mn in Series A funding on February 27, 2015, co-led by Wellington Partners, BioMed Partners, EMBL Ventures, and KfW Banking Group. The CEO, Volker Wedershoven, has a history in the biotech sector, although there are no details on other companies he has founded. ImevaX has completed one funding round to date, raising a total of EUR 7.5 mn and achieving a current company valuation of EUR 15.0 mn.ImevaX offers a range of therapeutic solutions designed to address autoimmune diseases, utilizing cutting-edge immunological and genetic research. Their products aim to provide targeted treatment options, enhancing patient outcomes in managing these complex conditions. ImevaX's innovations cater to the healthcare sector, focusing on delivering effective therapies that meet the needs of patients suffering from autoimmune disorders.ImevaX's revenue model is primarily based on securing funding for research and development projects as it continues to innovate in the biotech field. The company engages with investors to secure capital for its ongoing projects aimed at developing effective therapies for autoimmune diseases, ensuring a steady flow of resources to support its initiatives.ImevaX plans to leverage its recent funding of EUR 7.5 mn raised in Series A financing to enhance its research capabilities and expedite the development of new therapeutic products. The company aims to expand its presence in European markets and explore opportunities in North America by 2025. Additionally, the funding will support the launch of new treatments designed for specific autoimmune conditions, increasing the company's offerings and market reach.

## Funding rounds

- Series A, Feb 27, 2015, $8.5M — Wellington Partners, EMBL Ventures, KfW Banking Group, BioMed Partners, Armilar Venture Partners

## Investors

- Wellington Partners (https://capitalatlas.ai/funds/wellington-partners) — Series A
- EMBL Ventures (https://capitalatlas.ai/funds/embl-ventures) — Series A
- KfW Banking Group — Series A
- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series A
- Armilar Venture Partners (https://capitalatlas.ai/funds/armilar-venture-partners) — Series A